Vice President, Technical applications, Maxcyte Inc.
James BradyVice President, Technical applications, Maxcyte Inc.
James Brady, Ph.D., is Vice President of Tehcnical Applications and Customer Support at Maxcyte Inc., where he has worked since 2004. Prior to joining Maxcyte, Dr. Brady was a senior scientist at Genetic Therapy Inc. ( a Novartis subsidiary) and a group leader at MetaMorphix, Inc.
Process Science Manager, Thermo Fisher Scientific
Doan TranProcess Science Manager, Thermo Fisher Scientific
Doan Tran is a Process Science Manager, Thermo Fisher Scientific, responsible for technical engagement with customers to insure they gain maximum benefit from Gibco catalog or custom Bioproduction cell culture products. Her current role involves support of cell line development, process development, media development and technical operations consultation in cell culture.
Senior Manager, Cell Culture GE Healthcare
Bill WhitfordSenior Manager, Cell Culture GE Healthcare
William G Whitford is Sr. Manager, Cell Culture, GE Healthcare in Logan, UT with over 20 years experience in biotechnology product and process development. He joined the company 12 years ago as a team leader in R&D developing products supporting biomass expansion, protein expression and virus secretion in mammalian and invertebrate cell lines. Products he has commercialized include, defined and animal product-free hybridoma media, fed-batch supplements, and aqueous lipid dispersions. An invited lecturer at international conferences, he has published over 250 articles, book chapters and patents in a number of fields in the bioproduction arena. He now enjoys such industry activities as serving on the editorial advisory board for BioProcess International.
Claes Gustafsson, Ph.D
Chief Commercial Officer, ATUM
Claes Gustafsson, Ph.DChief Commercial Officer, ATUM
Greg Bleck, Ph.D.
Global Head of R & D, Biologics, Catalent Biologics
Greg Bleck, Ph.D.Global Head of R & D, Biologics, Catalent Biologics
Greg joined Catalent in 1998 as Director of Molecular Biology & Transgenics. He has a broad background in molecular biology, mammalian gene expression, cell culture and transgenic animals with 20 years experience with the organization.Greg has published over 55 research papers and co-authored three book chapters
SHAHRAM MISAGHI, PHD
Senior Scientist at Genentech, Inc
SHAHRAM MISAGHI, PHDSenior Scientist at Genentech, Inc
I am a senior scientist at the Cell Line Development department in Genentech. I have been in my current role since 2010. My research involves improving/innovating processes that result in generation of cell lines expressing bio-therapeutics (proteins and antibodies used as drugs) at high titers and with specific product quality attributes.
- Bachelor: University of California Berkeley, Molecular and Cell Biology.
- PhD: Harvard University, in Biological and Biomedical Sciences.
- Post-doctoral fellow at Massachusetts Institute of Technology (MIT) and Genentech.
Yemi Onakunle, PHD, MBA
SVP, Licensing and Business Development
Yemi Onakunle, PHD, MBASVP, Licensing and Business Development
Yemi has over 15 years of experience in drug manufacturing and cell line development. Prior to working at Selexis, Yemi was director of commercial development at Diosynth RTP Inc. and associate director of business development at Lonza Custom Manufacturing – organizations that provide process development and cGMP manufacturing services in mammalian production platforms. More recently, Yemi was head of sales and marketing at Bachem Americas Inc. - a contract manufacturing organization that focuses on peptides and complex organic molecules. In these positions, he has had a strong record of consistently growing the customer base and sales and expanding product offerings into new markets. Yemi is a member of the board of directors of VLP Biotech Inc, a vaccine development company that is based in San Diego, CA and has been a business advisor to several biopharmaceutical and drug delivery companies. Educated in the UK, Yemi holds a PhD from the University of Kent at Canterbury and an MBA from Imperial College Management School.
Dr. Michiel E. Ultee
Founder, Ulteemit BioConsulting
Dr. Michiel E. UlteeFounder, Ulteemit BioConsulting
Dr. Michiel “Mike” E. Ultee formed Ulteemit BioConsulting in October 2013 to offer expert consultation in the fields of process development and manufacture of protein therapeutics. With over 30 years experience in the development of biopharmaceuticals, from research through commercial manufacturing, Dr. Ultee offers both creative insight and a rich perspective into what it takes to turn a protein discovery into a therapeutic.